API Sector In India No Longer ‘Poor Cousin’ Of Formulations
Executive Summary
The active pharmaceuticals ingredients segment in India appears to be coming into its own, alongside signs of a revival in the overall sales growth of Indian generic firms in FY2019, a study by an Indian investment banking and consulting services firm has indicated.
You may also be interested in...
Indian API Firms Buoyant But Big Generics Firms See US-Led Swings
Leading Indian API firms are on a firm earnings footing and the evolving dynamics amid COVID-19 augur well for the segment, a new study by an Indian firm indicates, but notes that large cap generic firms in the country have seen sharp revenue growth swings over the decade.
India's API Firms Buoyant But Big Generic Cos See US-Led Swings
Leading Indian API firms are on a firm earnings footing and the evolving dynamics amid COVID-19 augur well for the segment, a new study by an Indian firm indicates, but notes that large cap generic firms in the country have seen sharp revenue growth swings over the decade.
Indian Pharma Regaining Form, Helped By Easing US Price Pressures
Indian drug makers are looking in much better shape as US pricing pressures ease and the domestic market regains its double-digit growth, analysts say.